All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ligelizumab
Therapeutic Area: Immunology Product Name: QGE031
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2021
Details:
Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Voclosporin
Therapeutic Area: Immunology Product Name: ISA247
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Aurinia Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 15, 2020
Details:
The dedicated facility will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ruxolitinib
Therapeutic Area: Immunology Product Name: INC424
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Incyte Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
Details:
Novartis announced that the Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Secukinumab
Therapeutic Area: Immunology Product Name: Cosentyx
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
Significant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx® at Week 12 vs. placebo, with improvements as early as Week.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Avacopan,Rituximab,Azathioprine
Therapeutic Area: Immunology Product Name: CCX168
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: ChemoCentryx
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2020
Details:
If approved, avacopan would be the first orally administered selective complement 5a receptor inhibitor, for the treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Iptacopan
Therapeutic Area: Immunology Product Name: LNP023
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2020
Details:
Iptacopan (LNP023) is a potential first-in-class, oral, potent and selective factor B inhibitor of the alternative complement pathway, which is involved in the underlying pathophysiology of IgA nephropathy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lenzilumab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Humanigen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 15, 2020
Details:
Collaboration to expand lenzilumab manufacturing capacity in advance of potential Emergency Use Authorization in 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Secukinumab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2020
Details:
Phase III PREVENT data show Cosentyx® 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to Week 521.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ruxolitinib
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2020
Details:
Data from Phase III REACH2 study demonstrate Jakavi can improve outcomes for patients with acute graft-versus-host disease (GvHD) who do not respond to first-line steroid treatment.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Secukinumab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2020
Details:
The positive opinion of Cosentyx is based on efficacy and safety outcomes from the PREVENT Phase III study which met the primary endpoint, achieving statistically significant improvements vs placebo.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
